JAC Advance Access published online on March 29, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn132
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Research letter |
MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii
1 Infectious Disease and Mycology Research Unit, Institut Municipal d'Investigació Mèdica, Parc de Recerca Biomèdica de Barcelona, Dr Aiguader 88, 08003 Barcelona, Spain 2 UDIMAS, Autonomous University of Barcelona, Dr Aiguader 80, 08003 Barcelona, Spain
* Correspondence address. Infectious Disease and Mycology Research Unit, Institut Municipal d'Investigació Mèdica, Parc de Recerca Biomèdica de Barcelona, Dr Aiguader 88, Barcelona 08003, Spain. Tel: +34-933160400; Fax: +34-933160410; E-mail: jmtorres@imim.es
Key Words: antifungals , triazoles , yeast , in vitro susceptibility
| The first 10% of the full text of this article appears below. |
Sir,
The major aetiological species of cryptococcosis is Cryptococcus neoformans, which is distributed especially in association with pigeon droppings, and the most common infection is in the CNS of immunocompromised patients. Cryptococcus gattii, previously considered a biovariety of C. neoformans, is the second agent of cryptococcosis; four basic serotypes have been described: A and D for C. neoformans and B and C for C. gattii. Although its geographical distribution is restricted, C. gattii is being reported in new areas and has produced epidemic outbreaks
| Funding |
|---|
| Transparency declarations |
|---|